United Therapeutics Corporation (UTHR:NASDAQ) closed at $591.17 on November 13, 2026, down 0.36% on the day. The stock trades 3.8% below its 52-week high of $614.23 and 29.7% above its 52-week low of $455.63. Over the past year, it gained 26.8%. United Therapeutics Corporation is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, UTHR closed higher on 124 days (49%). Its best day was February 25, 2026 (+13.03%) and its worst was November 5, 2026 (-7.03%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 1 time.
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops RemoSynch and RemUnity delivery systems for intravenous and subcutaneous Remodulin; esuberaprost and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation,...
Find more stocks like UTHR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.